PercAssist, Inc Revenue

About PercAssist, Inc

PercAssist, Inc. is addressing the #1 cause of death after a heart attack—cardiogenic shock. The PercAssist Percutaneous Synchronized Cardiac Assist (PSCA) System is designed for intrapericardial placement to provide left ventricular mechanical circulatory support for patients with cardiogenic shock. Its extravascular/extracardiac placement helps avoid many of the risks with current standard of care. Explore this $18B industry with us. Our novel technology is highly differentiated: - Simple, less invasive implant procedure - Extravascular/extracardiac placement→ Helps avoid hemolysis, stroke - No anticoagulants required→ Minimizes bleeding - No contrast imaging required → Reduces contrast-induced nephropathy Preliminary First-in-Human clinical results indicate early safety, feasibility, with positive signals of hemodynamic support. PercAssist is exploring acute and chronic applications—global market opportunities estimated between $9B and $18B.* Contact us to help bring this technology to the 140,000+ people who experience cardiogenic shock every year. Caution: The PercAssist PSCA System is for Investigational Use Only and is not for sale in the U.S. or outside the U.S. *PercAssist internal market estimates based on incidence/growth data for cardiogenic shock and heart failure.

View contact profiles from PercAssist, Inc